ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
about
Pathways for aberrant angiogenesis in pancreatic cancerSilencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer.Helicobacter pylori and interleukin-8 in gastric cancerHepatocellular carcinoma: Where there is unmet needMechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.The role of CXC chemokines in pulmonary fibrosis.Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer.First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.Tumor vascular changes mediated by inhibition of oncogenic signaling.Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cellsTargeting the EGFR signaling pathway in cancer therapy.Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.Targeted inhibition of kinases in cancer therapyPhosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors.Emerging drugs to treat squamous cell carcinomas of the head and neck.The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.Extracellular Matrix and Growth Factors Improve the Efficacy of Intramuscular Islet Transplantation.Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalizationTargeting HER2 Positive Breast Cancer with Chemopreventive Agents.Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamicsEGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation.A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status.Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cellsCombined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.STAT3-mediated coincidence detection regulates noncanonical immediate early gene induction.Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant gliomaInflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosisTherapeutic approaches to target cancer stem cells.Review of erlotinib in the treatment of advanced non-small cell lung cancer.Role of Epidermal Growth Factor-Triggered PI3K/Akt Signaling in the Migration of Medulloblastoma-Derived Cells.A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
P2860
Q24800215-057F809B-A724-4B37-B9E0-B85956B43B7AQ24814041-020EEAC9-30FC-40AD-8C94-05CC4AB94619Q26999701-37C2DE60-9A95-4C23-AEE5-484B1C9F8395Q28084046-7891ABB9-D051-4667-BAA6-4A932317A0AFQ30431758-47051830-3651-4F56-8FA0-E59430E82851Q30443091-CF648997-8DCA-4882-83DD-048E532852D0Q30557865-EFD8839F-D17C-4CB6-A877-DFE539D1FA51Q33206782-E94DFD64-89C2-4FDA-B714-16D7EB35DC08Q33441143-E4758A91-63D8-409C-BA30-36B32644A3A9Q33671385-90FF4CF3-D6E4-4D67-8169-89216E446605Q33947163-95FD81A9-CC67-47C8-B23C-EE72D30541E4Q34246558-C33ABAF1-46DE-43DA-950B-E0881DB4F36CQ34605162-9764C19F-039A-48A1-A78B-DC6F6D721639Q34683348-9B04F241-F445-4268-84FA-2F828687EE1BQ35082185-C3559AF8-1518-433A-8146-B531DE34C01EQ35098322-2DC20A3C-A332-40EA-97C9-14AF70333450Q35649008-D9A630AA-FF28-427C-85D8-FAF85682D820Q35810352-BBFBEA1B-9824-4322-A742-97E701E06607Q35893456-D2A45DE4-C522-4C21-8056-083B83172698Q36114852-ED492664-3F48-4397-AA03-9B9EA8557572Q36127636-CF954B6A-B8EF-47BB-B6D2-937EE7D19EF3Q36360133-0CF0EDCA-D7A3-4659-AE58-BDB9CB4EBA46Q36484566-B4269ACB-6F1E-4F06-BEBD-21EE99E86CA1Q36494583-046125BC-50D0-4596-AD8A-57DBFB73C9BAQ36598514-0FBA26D6-503C-4DFC-B762-198F722D96B3Q36611627-4C07D971-36EC-4548-95C1-39F301EE484FQ36616462-D1F06BB6-28F9-484B-8D7D-CF49C73E8EEBQ36616873-2D080532-430D-4269-8B21-48F8B9033680Q36673777-BE8935B9-B25E-42E8-B008-E6A845085B3CQ36755155-25730FA2-F6A3-4C93-B920-551EFF386603Q36796847-B56DD309-9355-4BE8-969B-BAA72D5ECC58Q36808787-BA5DFF11-CB73-4379-B69C-9269159D5DE5Q37096361-89317C1F-CBC3-42FA-AA50-4813B897F6B7Q37101643-E03DEAE5-E0BD-4158-B3A5-CC602B06D887Q37137412-BBD0D8CC-C6F3-4EA7-AA26-2B01EBE38FE1Q37290444-68E553D0-5290-4401-B8F7-6FEEFAFBBE45Q37322399-E6C2CA4B-3146-4771-95E6-74D42682395AQ37357251-E4100B10-A5A4-46C6-BE26-CBB6AFD539EDQ37581685-E670B955-0A0A-4A51-93BB-1CFD95A96C7AQ37594373-0087CC36-3995-422B-98DF-A5E3F8396707
P2860
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
ZD1839 (Iressa) induces antian ...... ctor receptor tyrosine kinase.
@ast
ZD1839 (Iressa) induces antian ...... ctor receptor tyrosine kinase.
@en
type
label
ZD1839 (Iressa) induces antian ...... ctor receptor tyrosine kinase.
@ast
ZD1839 (Iressa) induces antian ...... ctor receptor tyrosine kinase.
@en
prefLabel
ZD1839 (Iressa) induces antian ...... ctor receptor tyrosine kinase.
@ast
ZD1839 (Iressa) induces antian ...... ctor receptor tyrosine kinase.
@en
P2093
P1433
P1476
ZD1839 (Iressa) induces antian ...... actor receptor tyrosine kinase
@en
P2093
Akira Hirata
Mayumi Ono
Michihiko Kuwano
Seiji Naito
Soh-ichiro Ogawa
Takashi Kuwano
Takuro Kometani
P304
P407
P577
2002-05-01T00:00:00Z